Supemtek is included in latest 2022/23 Joint Committee on Vaccination and Immunisation (JCVI) recommendations for all eligible adult cohorts.1
Target influenza with Supemtek (Quadrivalent Influenza Vaccine, recombinant prepared in cell-culture), the first recombinant influenza vaccine in Europe. Supemtek is manufactured to offer an exact genetic match to the World Health Organization (WHO)-predicted viral strains.2,3
Supemtek quadrivalent influenza vaccine is indicated for active immunisation for the prevention of influenza disease in adults.2
A recent, self-controlled case series study showed that adults aged ≥40 years (median age of
68 years), without a history of heart attack or stroke, were at an increased risk of severe cardiovascular complications in the 1–3 days following a confirmed influenza infection.*4
Patients were at a 10x increased risk of a first heart attack and 8x increased risk of a first stroke.*4
Each year in the UK, influenza vaccination could help to reduce the number of influenza cases
and influenza-related premature deaths.5
Recombinant technology eliminates the possibility of adaptation or mutation by replicating only the haemagglutinin (HA) antigen direct from a genetic sequence. The resulting antigens are an exact genetic match to the target strain HA antigen.3,6
Supemtek contains 3x more HA antigen (45 mcg versus 15 mcg) per strain, compared with cell-
and egg-based standard-dose quadrivalent influenza vaccines.3
Supemtek demonstrated 30% greater relative efficacy (1% absolute efficacy) versus standard-dose egg-based quadrivalent inactivated influenza vaccine (QIVe), in preventing confirmed cases of influenza-like illness in adults ≥50 years of age, with respective influenza attack rates of
2.2% and 3.2 %.†3
Supemtek demonstrated a comparable safety profile to standard-dose egg-based QIVe.3,7
Randomised controlled trials support the efficacy and safety of Supemtek for active immunisation for the prevention of influenza disease in adults ≥18 years of age.3,7
Results from a European Centre for Disease Prevention and Control (ECDC) systematic literature review to assess the efficacy, effectiveness and safety of enhanced influenza vaccines (versus standard-dose or placebo) for the prevention of laboratory-confirmed influenza in adults ≥18 years of age suggested that Supemtek may offer ”better protection than no vaccination, or standard influenza vaccines.”(QIVe)8
*As measured by age- and season-adjusted incidence ratios for myocardial infarction (n=1,227) or stroke (n=762) in adults aged 40 years or older, in the 1-3 days following a laboratory-confirmed influenza infection. Adjusted IRs were 9.80 (95% CI: 2.37, 40.5) and 7.82 (95% CI: 1.07, 56.9) for myocardial infarction and stroke, respectively.4
†As measured by relative vaccine efficacy (rVE) in adults aged 50+ years, randomised 1:1 to receive single dose of Supemtek (n=4,303) or standard-dose egg-based QIVe (n=4,301) during the 2014/15 influenza season (95% CI: 10, 47 p=0.006). Influenza attack rates were 2.2.% and 3.2% for Supemtek and standard-dose QIVe, respectively. The lower bound (LB) of the 95% confidence interval met the pre-specified, exploratory criterion for superior rVE LB >9%. Primary endpoint: rVE against reverse transcription polymerase chain reaction-confirmed, protocol-defined, influenza-like illness caused by any influenza strain starting 14 days or more after vaccination.3
CI, confidence interval; ECDC, European Centre for Disease Prevention and Control; HA, haemagglutinin; JCVI, Joint Committee on Vaccination and Immunisation; LB, lower bound; QIVe, quadrivalent inactivated influenza vaccine; rVE, relative vaccine efficacy; WHO, World Health Organization.
Date of preparation: January 2022 | MAT-GB-2003349(v4.0)